The European Commission has officially approved Luxturna (voretigene neparvovec), Novartis AG’s one-time gene therapy for inherited retinal dystrophy caused by RPE65 gene mutations.
This is the company’s first move into gene therapy and the approval is something of a landmark for Novartis. What...
Welcome to Scrip
Create an account to read this article
Already a subscriber?